Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial
Authors:
- Constantin-Cristian TopriceanuCTConstantin-Cristian Topriceanu
- Christoffer Rasmus VissingCVChristoffer Rasmus Vissing
- Anna Axelsson RajaARAnna Axelsson Raja
- Sharlene M. DaySDSharlene M. Day
- Mark W. RussellMRMark W. Russell
- Alexandre C. PereiraAPAlexandre C. Pereira
- Steven D. ColanSCSteven D. Colan
- Anne M. MurphyAMAnne M. Murphy
- Charles CanterCCCharles Canter
- Richard G. BachRBRichard G. Bach
- Matthew T. WheelerMWMatthew T. Wheeler
- 1 June 2025
- journal article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (6) , e012393
Abstract
BACKGROUND: In hypertrophic cardiomyopathy (HCM), the mechanisms through which pathogenic sarcomere variants (G+) lead to left ventricular hypertrophy (LVH) are not understood. METHODS: VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) was a multicenter, double-blind, placebo-controlled, randomized trial testing valsartan’s ability to attenuate phenotypic progression in early sarcomeric (G+LVH+) and subclinical HCM (G+LVH‒). The outcome was a composite z-score reflecting change in cardiac remodeling from baseline to year 2 (end of study). Baseline and year 2 blood samples were used to quantify 276 proteins using a proximity extension assay (Olink, Sweden). We explored relative differences in protein abundance between early and subclinical HCM at baseline. In addition, we compared proteomic changes between baseline and year 2 in subclinical HCM participants who experienced phenotypic conversion to early HCM (convertors) versus nonconvertors; early HCM participants receiving valsartan versus placebo; and in association with changes in the phenotypic progression z-score. Comparisons were made using the t -test, Mann-Whitney U test, linear mixed models, and generalized linear models, correcting for multiple testing using a 5% false discovery rate RESULTS: Circulating proteins were analyzed in 192 participants (32 subclinical and 160 early HCM [81 allocated to valsartan]). NT-proBNP (N-terminal pro-B-type natriuretic peptide) differentiated early from subclinical HCM and tracked with phenotypic progression in early HCM (1-unit worsening in z-score associated with a 27% increase in NT-proBNP [95% CI, 17–37%]). Some extracellular matrix remodeling proteins showed a higher abundance (eg, tissue-type plasminogen activator) in early compared with subclinical HCM or tracked with disease progression (decorin) in early HCM. Some growth factors had a higher relative abundance in early HCM (eg, fibroblast growth factor-21). While no individual protein was able to distinguish phenotypic convertors from nonconvertors, multiprotein panels including lipocalin 2, lectin-like oxidized low-density lipoprotein receptor 1, and either NT-proBNP or interleukin-17 receptor A, could distinguish these groups. CONCLUSIONS: NT-proBNP was the most informative protein, showing a higher abundance in early compared with subclinical HCM and tracking with the phenotypic progression z-score in early-stage HCM. Studying pathways involving growth factors and extracellular matrix remodeling may yield additional insights into the mechanisms behind disease progression in sarcomevere variant carriers and early HCM. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01912534.Keywords
This publication has 26 references indexed in Scilit:
- Cardiac Remodeling in Subclinical Hypertrophic CardiomyopathyJAMA Cardiology, 2023
- Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide AnalysisMolecular & Cellular Proteomics, 2021
- Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialNature Medicine, 2021
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2021
- Chitinase-3 like-protein-1 function and its role in diseasesSignal Transduction and Targeted Therapy, 2020
- Gene therapy strategies in the treatment of hypertrophic cardiomyopathyPflügers Archiv - European Journal of Physiology, 2018
- The human protein atlas: A spatial map of the human proteomeProtein Science, 2017
- Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertensionJournal of the American Society of Hypertension, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimatesJournal of Clinical Epidemiology, 1995